Dr. Douglas Harrington has over 25 years of experience in the research, development, and translation into clinical use of innovative healthcare technology and services. Dr. Harrington was a resident member of one of the first heart transplant teams led by Dr. Jack Copeland from Stanford University. He co- founded one of the first clinical molecular biology laboratories in the U.S. with the Nebraska Lymphoma Study Group headed by Dr. Jim Armitage. Dr. Harrington has developed multiple patents including detection of residual cancer cells, catalytic heavy metal extraction, and a patent pending for diagnosis and classification of cardiac disease. Dr. Harrington has taken over 200 academic discoveries into clinical use, founded a number of public and private biotechnology companies, and his PULS (Protein Unstable Lesion Signature) Cardiac Test was the recipient of the 2016 ABL Grand Prize Award for Innovation in Healthcare. Dr. Harrington focuses on disease prevention and is Medical Director for the Tshimakain (T-creek) First Nation Research and Diagnostic laboratory in Spokane (the first Native American owned Cardiac research facility), a published author of numerous peer-reviewed papers, and a sought after speaker in the area of preventive medicine and technology development. Dr. Harrington received his BA in molecular biology, and MD from the University of Colorado Health Sciences Center, and is the Chairman & Laboratory Director of Predictive Health Diagnostics.